Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Rasco, D.W., Papadopoulos, K.P., Pourdehnad, M., Gandhi, A.K., Hagner, P.R., Li, Y., Wei, X., Chopra, R., Hege, K., DiMartino, J., et al. (2019). A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin cancer res, Vol.25 (1), pp. 90-98.  show abstract

Chopra, R., Sadok, A. & Collins, I. (2019). A critical evaluation of the approaches to targeted protein degradation for drug discovery. Drug discovery today: technologies, .

Schafer, P.H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M. & Chopra, R., et al. (2018). Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann rheum dis, Vol.77 (10), pp. 1516-1523.  show abstract

Hagner, P.R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S., Waldman, M.F., Flynt, E., Ramsay, A.G., Trotter, M., et al. (2017). Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. Br j haematol, Vol.179 (3), pp. 399-409.  show abstract

Collins, I., Wang, H., Caldwell, J.J. & Chopra, R. (2017). Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway. Biochem j, Vol.474 (7), pp. 1127-1147.  show abstract

Rychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J., Lu, L., Miller, K., Narla, R.K., Orlowski, R.Z., Raymon, H.K., et al. (2016). Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br j haematol, Vol.172 (6), pp. 889-901.  show abstract

Jourdan, M., Cren, M., Schafer, P., Robert, N., Duperray, C., Vincent, L., Ceballos, P., Cartron, G., Rossi, J.-., Moreaux, J., et al. (2016). Differential effects of lenalidomide during plasma cell differentiation. Oncotarget, Vol.7 (19), pp. 28096-28111.  show abstract

Wei, W., Shin, Y.S., Xue, M., Matsutani, T., Masui, K., Yang, H., Ikegami, S., Gu, Y., Herrmann, K., Johnson, D., et al. (2016). Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer cell, Vol.29 (4), pp. 563-573.  show abstract

van der Velden, J.L., Ye, Y., Nolin, J.D., Hoffman, S.M., Chapman, D.G., Lahue, K.G., Abdalla, S., Chen, P., Liu, Y., Bennett, B., et al. (2016). JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin transl med, Vol.5 (1), p. 36.  show abstract

Ear, J., Hsueh, J., Nguyen, M., Zhang, Q., Sung, V., Chopra, R., Sakamoto, K.M. & Lin, S. (2016). A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure. J genet genomics, Vol.43 (5), pp. 307-318.  show abstract

Bendell, J.C., Kelley, R.K., Shih, K.C., Grabowsky, J.A., Bergsland, E., Jones, S., Martin, T., Infante, J.R., Mischel, P.S., Matsutani, T., et al. (2015). A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer, Vol.121 (19), pp. 3481-3490.  show abstract

Lagrue, K., Carisey, A., Morgan, D.J., Chopra, R. & Davis, D.M. (2015). Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood, Vol.126 (1), pp. 50-60.  show abstract

Bjorklund, C.C., Lu, L., Kang, J., Hagner, P.R., Havens, C.G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015). Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood cancer j, Vol.5, p. e354.  show abstract

Hagner, P.R., Man, H.-., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C.G., Lu, G., Rychak, E., et al. (2015). CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood, Vol.126 (6), pp. 779-789.  show abstract

Krönke, J., Fink, E.C., Hollenbach, P.W., MacBeth, K.J., Hurst, S.N., Udeshi, N.D., Chamberlain, P.P., Mani, D.R., Man, H.W., Gandhi, A.K., et al. (2015). Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature, Vol.523 (7559), pp. 183-188.  show abstract

Chen, N., Brachmann, C., Liu, X., Pierce, D.W., Dey, J., Kerwin, W.S., Li, Y., Zhou, S., Hou, S., Carleton, M., et al. (2015). Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer chemother pharmacol, Vol.76 (4), pp. 699-712.  show abstract

Ear, J., Huang, H., Wilson, T., Tehrani, Z., Lindgren, A., Sung, V., Laadem, A., Daniel, T.O., Chopra, R. & Lin, S., et al. (2015). RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1. Blood, Vol.126 (7), pp. 880-890.  show abstract

Klinghoffer, R.A., Bahrami, S.B., Hatton, B.A., Frazier, J.P., Moreno-Gonzalez, A., Strand, A.D., Kerwin, W.S., Casalini, J.R., Thirstrup, D.J., You, S., et al. (2015). A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci transl med, Vol.7 (284), p. 284ra58.  show abstract

Schafer, P.H., Chen, P., Fang, L., Wang, A. & Chopra, R. (2015). The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J immunol res, Vol.2015, p. 906349.  show abstract

Lagrue, K., Chopra, R. & Davis, D. (2014). The immunomodulatory drug lenalidomide augments NK cell IFN-gamma secretion and lowers the threshold for NK cell activation. Journal of immunology, Vol.192.

Gandhi, A.K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014). Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br j haematol, Vol.164 (2), pp. 233-244.  show abstract

Chen, X., Díaz-Rodríguez, E., Ocio, E.M., Paiva, B., Mortensen, D.S., Lopez-Girona, A., Chopra, R., Miguel, J.S. & Pandiella, A. (2014). Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Mol cancer ther, Vol.13 (2), pp. 504-516.  show abstract

Gandhi, A.K., Kang, J., Havens, C.G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M.F., Thakurta, A., et al. (2014). Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN ). Br j haematol, Vol.164 (6), pp. 811-821.  show abstract

Wolin, E., Mita, M., Meyer, T., Bendell, J., Mahipal, A., Nemunaitis, J., Wong, L., Wu, X., Carmichael, J., Chopra, R., et al. (2014). Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET). Pancreas, Vol.43 (3), pp. 508-508.

Dussiot, M., Maciel, T.T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., et al. (2014). An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat med, Vol.20 (4), pp. 398-407.  show abstract

Suragani, R.N., Cadena, S.M., Cawley, S.M., Sako, D., Mitchell, D., Li, R., Davies, M.V., Alexander, M.J., Devine, M., Loveday, K.S., et al. (2014). Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat med, Vol.20 (4), pp. 408-414.  show abstract

Thakurta, A., Gandhi, A.K., Waldman, M.F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S.A., et al. (2014). Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia, Vol.28 (5), pp. 1129-1131.

Blocksidge, J., Glenn, M., Gandhi, A.K., Klippel, A., Pourdehnad, M., Chopra, R. & Kalakonda, N. (2014). CC-122 Has Robust Anti-Proliferative Activity in a Primary Chronic Lymphocytic Leukemia (CLL) Co-Culture Model and Is Superior to Lenalidomide. Blood, Vol.124 (21).

Carrancio, S., Markovics, J., Wong, P., Leisten, J., Castiglioni, P., Groza, M.C., Raymon, H.K., Heise, C., Daniel, T., Chopra, R., et al. (2014). An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br j haematol, Vol.165 (6), pp. 870-882.  show abstract

Schafer, P.H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J.F., Man, H.-., Muller, G.W., Stirling, D.I. & Chopra, R., et al. (2014). Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell signal, Vol.26 (9), pp. 2016-2029.  show abstract

Schafer, P., Chen, P., Fang, L., Wang, A. & Chopra, R. (2014). Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial. Arthritis & rheumatology, Vol.66, pp. S425-S425.

Schafer, P.H., Ye, Y., Wu, L., Kosek, J., Yang, Z., Liu, L., Thomas, M., Palmisano, M. & Chopra, R. (2014). The CUL4(CRBN) E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus. Arthritis & rheumatology, Vol.66, pp. S1176-S1177.

Chen, N., Li, Y., Ye, Y., Palmisano, M., Chopra, R. & Zhou, S. (2014). Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J clin pharmacol, Vol.54 (10), pp. 1097-1107.  show abstract

Zhang, L.-., Kosek, J., Wang, M., Heise, C., Schafer, P.H. & Chopra, R. (2013). Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br j haematol, Vol.160 (4), pp. 487-502.  show abstract

Mita, M.M., Arkenau, H.-., Bendell, J.C., Munster, P.N., Mahipal, A., Delord, J.-., Paz-Ares, L.G., Soria, J.-., Xu, S., Tran, T., et al. (2013). Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR plus ) breast cancer cell lines and patients (pts) with genetically characterized HR plus breast cancer in a Phase I clinical trial. Molecular cancer therapeutics, Vol.12 (11).

Gini, B., Zanca, C., Guo, D., Matsutani, T., Masui, K., Ikegami, S., Yang, H., Nathanson, D., Villa, G.R., Shackelford, D., et al. (2013). The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin cancer res, Vol.19 (20), pp. 5722-5732.  show abstract

Schafer, P.H., Ye, Y., Chen, P., Liu, Y., Bennett, B., Sutherland, D., Maroni, J., Palmisano, M., Horowitz, Z., Chopra, R., et al. (2013). Pharmacodynamic And Pharmacokinetic Assessment Of The C-Jun N-Terminal Kinase (JNK) Inhibitor Cc-930 In A Phase 2 Sequential Ascending Dose Study In Idiopathic Pulmonary Fibrosis (ipf). American journal of respiratory and critical care medicine, Vol.187.

Gandhi, A.K., Shi, T., Li, M., Jungnelius, U., Romano, A., Tabernero, J., Siena, S., Schafer, P.H. & Chopra, R. (2013). Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. Plos one, Vol.8 (11), p. e80437.  show abstract

Mamidipudi, V., Shi, T., Brady, H., Surapaneni, S., Chopra, R., Aukerman, S.L., Heise, C. & Sung, V. (2012). Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells. Cancer chemother pharmacol, Vol.69 (4), pp. 965-976.  show abstract

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, Vol.26 (11), pp. 2326-2335.  show abstract

Zeldis, J.B., Knight, R., Hussein, M., Chopra, R. & Muller, G. (2011). A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann n y acad sci, Vol.1222, pp. 76-82.  show abstract

Yamaguchi, M., Fujimura, K., Kanegane, H., Toga-Yamaguchi, H., Chopra, R. & Okamura, N. (2011). Mislocalization or low expression of mutated Shwachman-Bodian-Diamond syndrome protein. Int j hematol, Vol.94 (1), pp. 54-62.  show abstract

Lopez-Girona, A., Heintel, D., Zhang, L.-., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J.B., Schafer, P.H., Schreder, M., Bolomsky, A., et al. (2011). Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br j haematol, Vol.154 (3), pp. 325-336.  show abstract

Heise, C., Carter, T., Schafer, P. & Chopra, R. (2010). Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert rev anticancer ther, Vol.10 (10), pp. 1663-1672.  show abstract

Sirohi, B., Powles, R.L., Chopra, R., Russell, N., Byrne, J.L., Prentice, H.G., Potter, M. & Koblinger, S. (2006). A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone marrow transplant, Vol.38 (1), pp. 47-51.  show abstract

Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., et al. (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, Vol.104 (13), pp. 3865-3871.  show abstract

Powles, R., Sirohi, B., Chopra, R., Fitzgerald, C., Russel, N., Prentice, G., McCullough, H., Pac-Soo, A. & Koblingner, S. (2001). Assessment of maximum tolerated dose (MTD) and pharmacokinetics (PK) of FK463 in neutropenic patients after haematopoetic stem cell transplantation. Blood, Vol.98 (11), pp. 361B-361B.

Powles, R., Sirohi, B., Chopra, R., Russel, N., Prentice, G., Kulkarni, S., Rudin, C., Menon, A., Pac-Soo, A. & Koblingner, S., et al. (2001). Use of FK 463, a novel echinocandin analog in patients undergoing autologous or allogeneic stem cell transplantation for haematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls. Blood, Vol.98 (11), pp. 208A-208A.

Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., et al. (2001). In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy, Vol.3 (3), pp. 197-201.  show abstract

Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., Peggs, K., Verfuerth, S., Pettengell, R., Marsh, J.C., et al. (2000). In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, Vol.96 (7), pp. 2419-2425.  show abstract

Kottaridis, P.D., Chakraverty, R., Milligan, D.W., Chakrabarti, S., Robinson, S., Chopra, R., Pettengell, R., Marsh, J., Mahendra, P., Schey, S., et al. (1999). A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. Blood, Vol.94 (10), pp. 348A-348A.

Linch, D.C., Scarffe, H., Proctor, S., Chopra, R., Taylor, P.R., Morgenstern, G., Cunningham, D., Burnett, A.K., Cawley, J.C. & Franklin, I.M., et al. (1993). Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone marrow transplant, Vol.11 (4), pp. 307-311.  show abstract

Chopra, R., Goldstone, A.H., McMillan, A.K., Powles, R., Smith, A.G., Prentice, H.G., Reid, C., Marcus, R., Bell, A. & Milligan, D., et al. (1991). Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. J clin oncol, Vol.9 (10), pp. 1840-1847.  show abstract

Ren, Y., Wang, M., Couto, S., Hansel, D.E., Miller, K., Lopez-Girona, A., Bjorklund, C.C., Gandhi, A.K., Thakurta, A., Chopra, R., et al. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. Appl immunohistochem mol morphol, Vol.24 (10), pp. 695-702.  show abstract


Conferences

Ren, Y., Wang, M., Couto, S., Hansel, D., Gandhi, A.K., Hagner, P., Thakurta, A., Chopra, R. & Breider, M. (2015). Dual-color immunohistochemistry assays for measuring Aiolos and Ikaros proteins in multiple myeloma patient samples, CANCER RESEARCH, Vol.75.

Amatangelo, M.D., Bjorklund, C.C., Gandhi, A.K., Klippel, A., Daniel, T., Chopra, R., Trotter, M. & Thakurta, A. (2015). IMiD (R) Immunomodulatory Agents Promote Apoptosis in Multiple Myeloma Cells through Induction of TRAIL Expression, BLOOD, Vol.126 (23).

Gandhi, A.K., Vincent, R., Carpio, C., Stoppa, A.-., Gharibo, M.M., Damian, S., Rasco, D.W., Ysebaert, L., Cordoba, R., Santoro, A., et al. (2015). CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma, BLOOD, Vol.126 (23).

Hagner, P., Chiu, H., Ortiz-Estevez, M., Biyukov, T., Brachman, C., Trneny, M., Arcaini, L., Morschhauser, F., Thyss, A., Stilgenbauer, S., et al. (2015). Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity, BLOOD, Vol.126 (23).

Amatangelo, M.D., Neri, P., Ortiz, M., Bjorklund, C.C., Gandhi, A.K., Klippel, A., Bahlis, N.J., Daniel, T., Chopra, R., Trotter, M., et al. (2015). Resistance to Lenalidomide in Multiple Myeloma Is Associated with a Switch in Gene Expression Profile, BLOOD, Vol.126 (23).

Kleiman, R.B., Chopra, R., Hans, D.H., Hege, K., James, A.J., Wang, X., Wu, X. & O'Mara, E. (2015). A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study, BLOOD, Vol.126 (23).

Schafer, P., Ye, Y., Wu, L., Kosek, J., Yang, Z., Liu, L., Thomas, M., Palmisano, M. & Chopra, R. (2015). THE CRL4 CEREBLON E3 UBIQUITIN LIGASE MODULATOR CC-220 INDUCES DEGRADATION OF THE TRANSCRIPTION FACTORS AIOLOS AND IKAROS: IMMUNOMODULATION IN HEALTHY VOLUNTEERS AND RELEVANCE TO SYSTEMIC LUPUS ERYTHEMATOSUS, ANNALS OF THE RHEUMATIC DISEASES, Vol.74, p.113.

Cappellini, M.D., Porter, J., Origa, R., Forni, G.L., Voskaridou, E., Taher, A.T., Laadem, A., Galacteros, F., Miteva, D., Sung, V., et al. (2015). INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA, HAEMATOLOGICA, Vol.100, pp.17-18.

Porter, J., Cappellini, M.D., Origa, R., Forni, G.L., Laadem, A., Galacteros, F., Voskaridou, E., Miteva, D., Sung, V., Chopra, R., et al. (2014). INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA, HAEMATOLOGICA, Vol.99, p.230.

Schafer, P., Chen, P., Fang, L., Wang, A. & Chopra, R. (2014). APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: PHARMACODYNAMIC RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL (PALACE 1), ANNALS OF THE RHEUMATIC DISEASES, Vol.73, pp.739-740.

Ren, Y., Wang, M., Couta, S., Hansel, D., Miller, K., Lopez-Girona, A., Bjorklund, C.C., Gandhi, A.K., Thakurta, A., Chopra, R., et al. (2014). Dual-Color CRBN/CD138 Immunohistochemistry Assay for Measuring Cereblon Protein in Samples from Patients with Multiple Myeloma, BLOOD, Vol.124 (21).

Hagner, P., Wang, M., Couto, S., Breider, M., Fontanillo, C., Trotter, M., Bjorklund, C.C., Havens, C.G., Raymon, H.K., Narla, R.K., et al. (2014). CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways, BLOOD, Vol.124 (21).

Ribrag, V., Damien, S., Gharibo, M., Gironella, M., Santoro, A., Rasco, D.W., Edenfield, W., Wei, X., James, A., Hagner, P., et al. (2014). CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma, BLOOD, Vol.124 (21).

Bjorklund, C.C., Havens, C.G., Hagner, P.R., Gandhi, A.K., Wang, M., Amatangelo, M.D., Lu, L., Wang, H., Breider, M., Ren, Y., et al. (2014). Degradation of Aiolos and Ikaros Followed By Downregulation of c-Myc and then IRF4 Leads to Programmed Cell Death in Myeloma Cells Sensitive to IMiDs (R) Immunomodulatory Compounds, BLOOD, Vol.124 (21).

Hollenbach, P., Lu, L., Gandhi, A.K., Chopra, R. & MacBeth, K.J. (2014). Lenalidomide Promotes Degradation of Casein Kinase 1a (CK1a) through Cereblon: Implications for the Efficacy of Lenalidomide in MDS and AML, BLOOD, Vol.124 (21).

Havens, C.G., Bjorklund, C., Kang, J., Ortiz, M., Fontanillo, C., Amatangelo, M., Lu, L., Neri, P.E., Lopez-Girona, A., Bahlis, N.J., et al. (2014). IMiDs Immunomodulatory Agents Regulate InterferonStimulated Genes through Cereblon-Mediated Aiolos Destruction in Multiple Myeloma (MM) Cells: Identification of a Novel Mechanism of Action and Pathway for Resistance, BLOOD, Vol.124 (21).

Siegel, D.S., Agajanian, R., Gaur, R., Karamiou, K., Kaya, H., Sturniolo, M., Ricafort, R.J., Larkins, G., Srinivasan, S., Chopra, R., et al. (2014). MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX), JOURNAL OF CLINICAL ONCOLOGY, Vol.32 (15).

Chen, N., Li, Y., Ye, Y., Palmisano, M., Chopra, R. & Zhou, S. (2014). Population pharmacokinetics (PK) and exposure-neutropenia relationship of nab-paclitaxel (nab-P) in patients (pits) with solid tumors, JOURNAL OF CLINICAL ONCOLOGY, Vol.32 (15).

Ellingson, B.M., Cloughesy, T.F., Munster, P.N., Shih, K.C., Bendell, J.C., James, A., Tong, Z., Trowe, T., Chopra, R. & Hege, K., et al. (2014). Correlation of intratumoral metabolic changes measured with 18F-FDG PET parametric response maps with concentrations of CC-223, a TORC 1/2 kinase inhibitor, in human glioblastoma., JOURNAL OF CLINICAL ONCOLOGY, Vol.32 (15).

Meyer, T., Mahipal, A., Bendel, J., Nemunaitis, J., Mita, M., Wong, L., Wu, X., Chopra, R., Hege, K. & Wolin, E., et al. (2014). Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET), NEUROENDOCRINOLOGY, Vol.99 (3-4), p.276.

Schafer, P., Rychak, E., Mendy, D., Parton, S., Capone, L., Lopez-Girona, A., Cedzik, D., Kosek, J., Zhang, L.-. & Chopra, R., et al. (2013). Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity, ARTHRITIS AND RHEUMATISM, Vol.65, p.S17.

Lagrue, K., Chopra, R. & Davis, D.M. (2013). The immunomodulatory drug Lenalidomide alters the threshold for NK cell activation and augments NK cell effector functions, IMMUNOLOGY, Vol.140, p.71.

Liu, X., Brachmann, C., Hong, S., Wu, S., Tong, Z., De, T., Foss, W., Kumar, G., Surapaneni, S., Chopra, R., et al. (2013). Albumin and paclitaxel co-localize in endocytic vesicles in HUVEC cells, and uptake is blocked by Cremophor EL., CANCER RESEARCH, Vol.73 (8).

Goy, A., Ribrag, V., Varga, A., Witzig, T.E., Ocio, E.M., Paz-Ares, L.G., Mita, M.M., Meyer, T., Munster, P.N., Mahipal, A., et al. (2013). Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Mita, M.M., Wolin, E.M., Meyer, T., Nemunaitis, J.J., Bergsland, E.K., Mahipal, A., Wong, L., Wu, X., Carmichael, J., Chopra, R., et al. (2013). Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET)., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Varga, A., Mita, M.M., Wu, J.J., Nemunaitis, J.J., Cloughesy, T.F., Mischel, P.S., Bendell, J.C., Shih, K.C., Paz-Ares, L.G., Mahipal, A., et al. (2013). Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Wong, L., Liu, Y., Wu, X., Bauer, D., Chen, B., Hege, K., Chopra, R., Bendell, J., Munster, P. & Xu, S., et al. (2012). Biomarker Development for the Pharmacodynamic Assessment of CC-223, a Potent and Selective mTOR Kinase Inhibitor, in Phase I Clinical Trials, EUROPEAN JOURNAL OF CANCER, Vol.48, p.136.

Carrancio, S., Markovics, J.A., Wong, P., Leisten, J., Groza, M.C., Raymon, H.K., Heise, C., Chopra, R., Daniel, T.O. & Sung, V., et al. (2012). Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin, BLOOD, Vol.120 (21).

Schafer, P.H., Rychak, E., Mendy, D., Parton, A., Capone, L., Lopez-Girona, A., Evans, J.F., Daniel, T.O. & Chopra, R. (2012). Targeting Cereblon with the High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent for B Cell Dyscrasias, BLOOD, Vol.120 (21).

Chen, N., Laadem, A., Sherman, M.L., Zhou, S., Sung, V., Palmisano, M. & Chopra, R. (2012). Exposures and Erythropoietic Responses to Sotatercept (ACE-011) in Healthy Volunteers and Cancer Patients: Implications for Mechanism of Action, BLOOD, Vol.120 (21).

Gandhi, A.K., Mendy, D., Parton, A., Wu, L., Kosek, J., Zhang, L.-., Capone, L., Lopez-Girona, A., Schafer, P.H. & Chopra, R., et al. (2012). CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers, BLOOD, Vol.120 (21).

Gandhi, A.K., Avet-Loiseau, H., Waldman, M., Thakurta, A., Aukerman, S.L., Chen, G., Mendy, D., Rychak, E., Miller, K., Gaidarova, S., et al. (2012). Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138(+) multiple Myeloma Cells, BLOOD, Vol.120 (21).

Carrancio, S., Markovics, J.A., Wong, P., Leisten, J., Groza, M.C., Raymon, H.K., Heise, C., Chopra, R., Daniel, T.O. & Sung, V., et al. (2012). Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin, BLOOD, Vol.120 (21).

Dussiot, M., Maciel, T., Fricot, A., Veiga, J., Paubelle, E., Payen, E., Beuzard, Y., Ribeil, J.-., Arlet, J.-., Courtois, G., et al. (2012). Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in beta-Thalassemia, BLOOD, Vol.120 (21).

Shih, K.C., Bendell, J.C., Reinert, A., Jones, S., Kelley, R.K., Infante, J.R., Korn, M., Hege, K., Chopra, R., Xu, S., et al. (2012). Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Bjorklund, C.C., Aukerman, S.L., Lopez-Girona, A., Hussein, M., Chopra, R., Kuiatse, I., Kuhn, D.J., Wei, C. & Orlowski, R.Z. (2011). Targeting the Wnt/beta-Catenin Signaling Pathway and CD44-Mediated Adhesion As a Rational Approach to Overcome Lenalidomide Resistance in Multiple Myeloma, BLOOD, Vol.118 (21), p.422.

Lopez-Girona, A., Mendy, D., Miller, K., Gandhi, A.K., Kang, J., Carmel, G., Abbasian, M., Mahmoudi, A., Jackson, P., Cathers, B., et al. (2011). Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide, BLOOD, Vol.118 (21), p.335.

Gaidarova, S., Mendy, D., Heise, C., Aukerman, S.L., Daniel, T., Chopra, R. & Lopez-Girona, A. (2010). Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins, to Enhance Rituximab Immune Recognition of Malignant B-Cells, BLOOD, Vol.116 (21), p.1173.

In this section

Publications